Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model

Cancer Letters

Volumn 202, Issue 2, 2003, Pages 153-159

  Huang, Lan ^a   Ohno, Tadao ^a,b  

^a RIKEN   (Japan)

^b WASEDA UNIVERSITY   (Japan)

Author keywords

Antitumor immunity; Paraformaldehyde; Tumor vaccine

Indexed keywords

ADJUVANT; CD4 ANTIGEN; GAMMA INTERFERON; PICIBANIL; TUBERCULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR IMMUNITY; VACCINATION;

MURINAE;

EID: 0344009737     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00479-8     Document Type: Article

References (19)

1. Moingeon P. Cancer vaccines. Vaccine. 19:2001;1305-1326.
2. Zeh H.J., Stavely-O'Carroll K., Choti M.A. Vaccines for colorectal cancer. Trends Mol. Med. 7:2001;307-313.
3. Morris R.J., Barber P.C. Fixation of Thy-1 in nervous tissue for immunohistochemistry: a quantitative assessment of the effect of different fixation conditions upon retention of antigenicity and the cross-linking of Thy-1. J. Histochem. Cytochem. 31:1983;263-274.
4. Liu S.Q., Saijo K., Todoroki T., Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumor sections. Nat. Med. 1:1995;267-271.
5. Horiuchi K., Tsurushima H., Kim B.S., Liu S.Q., Saijo K., Nukiwa T., Matsumura M., Ohno T. Expansion of human autologous cytotoxic T lymphocytes on fixed target tumor cells. Cytotechnology. 26:1998;119-124.
6. Peng B.G., Liu S.Q., Kuang M., He Q., Totsuka S., Huang L., Huang J.F., Lu M.D., Liang L.J., Leong K.W., Ohno T. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn J. Cancer Res. 93:2002;363-368.
7. Fujimoto T., Duda R.B., Szilvasi A., Chen X., Mai M., O'Donnell M.A. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J. Immunol. 158:1997;5619-5626.
8. Takahashi K., Harauchi D., Kimura S., Saito S., Monden Y. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Int. J. Immunopharmacol. 20:1998;375-388.
9. Sakamoto J., Teramukai S., Watanabe Y., Hayata Y., Okayasu T., Nakazato H., Ohashi Y. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J. Immunother. 24:2001;250-256.
10. De Silva B.S., Egodage K.L., Wilson G.S. Purified protein derivative (PPD) as an immunogen carrier elicits high antigen specificity to haptens. Bioconjug. Chem. 10:1999;496-501.
11. Darlington G.J., Bernhard H.P., Miller R.A., Ruddle F.H. Expression of liver phenotypes in cultured mouse hepatoma cells. J. Natl Cancer Inst. 64:1980;809-819.
12. Naito M., Seno S. Importance of antigen-lymphocyte interaction in establishment of cellular immunity. Cell Biol. Int. Rep. 5:1981;675-681.
13. + T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer. 87:2000;391-398.
14. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., Hodi F.S., Liebster L., Lam P., Mentzer S., Singer S., Tanabe K.K., Cosimi A.B., Duda R., Sober A., Bhan A., Daley J., Neuberg D., Parry G., Rokovich J., Richards L., Drayer J., Berns A., Clift S., Cohen L.K., Mulligan R.C., Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA. 95:1998;13141-13146.
15. Wei Y.Q., Wang Q.R., Zhao X., Yang L., Tian L., Lu Y., Kang B., Lu C.J., Huang M.J., Lou Y.Y., Xiao F., He Q.M., Shu J.M., Xie X.J., Mao Y.Q., Lei S., Luo F., Zhou L.Q., Liu C.E., Zhou H., Jiang Y., Peng F., Yuan L.P., Li Q., Wu Y., Liu J.Y. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 6:2000;1160-1166.
16. Ma Z., Zhou S.J., Wu K.C., Pan B.R., Qiao T.D., Chen B.J., Fan D.M. Immuno-protective effect of tumor cell vaccine on Kunming mice bearing Ehrlich ascites tumor. World J. Gastroenterol. 4:1998;404-408.
17. Dredge K., Marriott J.B., Todryk S.M., Muller G.W., Chen R., Stirling D.I., Dalgleish A.G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168:2002;4914-4919.
18. Ji H., Wang T.L., Chen C.H., Pai S.I., Hung C.F., Lin K.Y., Kurman R.J., Pardoll D.M., Wu T.C. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 10:1999;2727-2740.
19. Shi S.R., Cote R.J., Taylor C.R. Antigen retrieval techniques: current perspectives. J. Histochem. Cytochem. 49:2001;931-937.